Triparna Sen, Associate Professor, Icahn School of Medicine at Mount Sinai, shared a post on X:
“I am happy to share our brief report in Frontiers – Immunology highlighting the role of CD38-mediated immunosuppression as a potential mechanism of tumor cell escape from PDL1 inhibition in small-cell lung cancer.
SCLC is characterized by an immunosuppressed phenotype and immunotherapy with or without chemotherapy often has a modest benefit in only a minority of patients.
Our study provides preliminary evidence and a future direction for exploring: CD38 as a potential biomarker of ICB resistance… CD38 blockade as a potential combination strategy for chemoimmunotherapy in SCLC…
The work was led by a fantastic postdoc Dr. Hirokazu Taniguchi and I am grateful to all my co-authors- Drs. Shweta Chavan, Andrew Chow, Joseph Chan, Hiroshi Mukae, and Charles M. Rudin for their help and support. Â The underlying mechanism of ubiquitous immune escape in SCLC and biomarkers of immunotherapy response is an active area of investigation at the Sen Lab.”
Role of CD38 in anti-tumor immunity of small cell lung cancer
Authors:
